— January 27, 2026 · “Pseudo Leukotrienes” and the Free-Radical Rethink of Severe Asthma

For more than twenty years, the medical story of severe asthma has revolved around a family of inflammatory molecules called leukotrienes — the reason drugs such as montelukast (Singulair) exist. A study featured in the January 2026 issue of the Journal of Allergy and Clinical Immunology, which drew wide news coverage in late January, argues that a second and entirely different set of molecules may be doing a large share of the damage. The researchers call them “pseudo leukotrienes,” and the twist is that the body does not build them with enzymes at all — it makes them by accident, through runaway free-radical chemistry.

Table of Contents

1. 1. What the Study Found
2. 2. How Pseudo Leukotrienes Form
3. 3. The Numbers
4. 4. What It Could Mean
5. 5. Honest Caveats
6. 6. The Takeaway
7. Sources

1. What the Study Found

A team led by chemist Robert Salomon (the Charles Frederic Mabery Professor of Research in Chemistry at Case Western Reserve University), working with collaborators at the University of Toledo and Cleveland Clinic Children’s Hospital, identified a previously overlooked family of molecules they named pseudo leukotrienes (abbreviated øLTs). These compounds closely mimic the structure of the classic cysteinyl leukotrienes — LTC4, LTD4, and LTE4 — that have anchored asthma science for decades. Crucially, the look-alikes appear to switch on the same cellular receptor, so the body reads them as the real thing: a signal to tighten the airways, pour out mucus, and recruit inflammatory cells.

2. How Pseudo Leukotrienes Form

The mechanism is what makes the paper interesting. Genuine cysteinyl leukotrienes are manufactured on a controlled enzymatic assembly line: the enzyme 5-lipoxygenase acts on arachidonic acid, a fatty acid in cell membranes, to produce a precise product. Pseudo leukotrienes skip that assembly line entirely. Instead, free radicals add oxygen directly to the same fatty acid in an uncontrolled reaction — a process called radical-induced lipid oxidation, or lipid peroxidation.

A useful analogy: the enzyme pathway is a factory carefully stamping out one part, while the free-radical pathway is a fire in the warehouse that happens to spit out debris shaped like that same part. Because the pseudo leukotrienes are made by chemistry rather than by an enzyme, drugs designed to block the enzyme (such as zileuton) or to block the receptor (such as montelukast) do not necessarily shut them off. That detail may help explain a long-standing clinical frustration: leukotriene-blocking medicines work well for some people with asthma and barely at all for others.

3. The Numbers

When the team measured these molecules in urine, people with severe asthma had pseudo leukotriene levels roughly four to five times higher than healthy comparison subjects, and the levels tracked with how severe the disease was. The researchers also reported a plausible reason the molecules run wild in some patients: people with asthma may carry weaker antioxidant and enzyme defenses — the built-in systems that normally neutralize free radicals before they can damage fats and proteins. The full paper, “Radical-induced lipid oxidation produces a torrent of leukotriene-like agonists in severe asthma,” appears in Journal of Allergy and Clinical Immunology 2026;157(1):99 (published online in October 2025), DOI 10.1016/j.jaci.2025.09.027.

4. What It Could Mean

Two practical directions follow. The first is measurement. Because pseudo leukotrienes show up in urine and rise with severity, they are a candidate biomarker — a simple, non-invasive way to grade how bad someone’s asthma is, track whether a treatment is working, or flag failing antioxidant defenses before the disease worsens.

The second is strategy. If a meaningful share of asthma inflammation comes from free-radical chemistry rather than an enzyme, then the smarter target may be the chemistry itself. Salomon framed it plainly: preventing the free-radical processes would be preferable to merely “blocking the receptor” after the damaging molecules have already formed. The authors also note the same radical mechanism could be relevant beyond asthma — in RSV and bronchiolitis, in COPD, and potentially in other inflammatory conditions.

5. Honest Caveats

This is an important lead, not a finished answer, and it is worth being clear about the limits:

• It is an association, not a cure. The study shows that pseudo leukotrienes are elevated and correlate with severity. It does not show that lowering them makes asthma better — that would require a treatment trial that has not yet been done.
• It does not mean antioxidant pills treat asthma. The tempting leap is to reach for vitamin C, vitamin E, or N-acetylcysteine. But randomized trials of general antioxidant supplements in asthma have been mixed to disappointing. This paper offers a mechanism that could explain a benefit; it is not evidence that over-the-counter antioxidants control the disease.
• There is no clinical test yet. Measuring urinary pseudo leukotrienes is a research technique today, not something your doctor can order. The findings also need replication in larger and more diverse groups of patients.
• Current treatment stands. Inhaled steroids, bronchodilators, biologics, and leukotriene blockers remain the standard of care. Nobody should stop or change an asthma medication based on this discovery.

6. The Takeaway

The value of this work is conceptual: it shifts part of the asthma story from “block the receptor” toward “prevent the chemistry that keeps flipping the switch.” That reframing could eventually yield a urine test for severity and a new class of antioxidant-directed therapies — but “eventually” means years of validation and clinical trials, not months. If you live with asthma, the practical message is unchanged: keep following your current action plan, and talk to your clinician before altering anything. What is genuinely new is the direction of travel, and it is a promising one.

Sources

1. Salomon RG, et al. Radical-induced lipid oxidation produces a torrent of leukotriene-like agonists in severe asthma. Journal of Allergy and Clinical Immunology. 2026;157(1):99. DOI 10.1016/j.jaci.2025.09.027 — full text at jacionline.org
2. ScienceDaily. “Scientists may have been wrong about what causes asthma.” January 27, 2026. sciencedaily.com/releases/2026/01/260127010147.htm
3. U.S. News & World Report (HealthDay). “New Discovery Could Change How Asthma Is Treated, Scientists Say.” January 28, 2026. usnews.com
4. Respiratory Therapy. “‘Pseudo Leukotrienes’ May Cause Asthma.” January 2026. respiratory-therapy.com
5. PubMed topic search: pseudo leukotrienes asthma radical lipid oxidation
6. PubMed topic search: cysteinyl leukotrienes asthma oxidative stress

Back to Table of Contents